Clinical Evidence

Prescription precision.
Decades of evidence.

RevelleCare's formulations are built on a body of peer-reviewed research spanning 30+ years of dermatology, endocrinology, and clinical trial data. This is not wellness marketing — this is medicine.

How menopause changes skin at the cellular level

Estrogen acts on specific nuclear receptors — ERα and ERβ — expressed in keratinocytes, fibroblasts, sebaceous glands, and hair follicles. These receptors are the master regulators of the skin's structural integrity.

During perimenopause and menopause, circulating estrogen falls by 65–80%. The downstream consequences are profound: collagen synthesis slows, fibroblast activity decreases, transepidermal water loss increases, and the basement membrane thins.

Critically, the skin loses approximately 30% of its collagen in the first five years after menopause — a rate that no antioxidant cream or cosmetic serum can counteract without targeting the hormonal root cause.1

Why over-the-counter is not enough

Cosmetic actives (retinol, peptides, niacinamide) cannot bind estrogen receptors. Only prescription-strength topical estrogens — estradiol and estriol — act at the receptor level to restore what menopause takes away.

30%

of dermal collagen lost in the first 5 years post-menopause

Castelo-Branco et al., 1992

ERα / ERβ

Estrogen receptors in fibroblasts, keratinocytes & sebaceous glands

Thornton, 2002 — NAMS review

65–80%

decline in circulating estrogen from perimenopause to menopause

Endocrine Society Guidelines

2.1%

per year ongoing collagen loss if untreated after menopause

Brincat et al., 1985

Active Ingredient

Topical Estradiol
The gold standard active

Estradiol (17β-estradiol) is the primary endogenous estrogen and the most clinically studied topical active for menopausal skin aging.

Study Concentration Outcome Result
Moraes et al., 2009
Journal of Dermatological Science
0.01% Epidermal thickness +75% increase
Schmidt et al., 1996
International Journal of Dermatology
0.01% + Estriol 0.3% Wrinkle reduction 61–100%
Fuchs et al., 2003
Maturitas
0.01% Dermal collagen density +38% increase
Brincat et al., 1983
British Medical Journal
Topical application Skin collagen content Significantly restored
Callens et al., 1996
Maturitas
0.01% Skin hydration + elasticity Significant improvement

Mechanism of Action

1
Receptor Binding

Estradiol binds ERα and ERβ in dermal fibroblasts, activating transcription factors that upregulate collagen I and III synthesis genes.

2
Collagen Stimulation

Upregulation of TGF-β and VEGF pathways accelerates fibroblast activity and angiogenesis, improving oxygen and nutrient delivery to the dermis.

3
Barrier Restoration

Estradiol modulates keratinocyte differentiation, restoring stratum corneum integrity and reducing transepidermal water loss.

Active Ingredient

Topical Estriol
Gentle potency, proven results

Estriol is the weakest of the three endogenous estrogens, but its preferential affinity for ERβ — the receptor abundant in skin — makes it uniquely effective topically with a lower systemic risk profile.

Clinical Outcomes

+88% improvement in skin elasticity (Alloy/Draelos, 2024 — Estriol 0.3%)
61–100% wrinkle reduction in combination with estradiol (Schmidt, 1996)
ERβ preferred receptor in skin — estriol has 3× higher ERβ affinity than ERα
Low systemic absorption minimizes systemic estrogen exposure when applied topically

Why Estriol in Both Formulations?

RevelleCare's Estrogen Repair Cream includes estriol at 0.3% alongside estradiol 0.01%, providing complementary receptor activation — estradiol drives ERα-mediated collagen and elastin production, while estriol addresses the ERβ-regulated keratinocyte differentiation that governs barrier function.

In the Night Renewal Cream, low-dose estriol 0.03% serves as a barrier-protective counterpart to tretinoin — mitigating retinoid-associated skin irritation while preserving the hormonal support for overnight regeneration.

Estriol and safety

Multiple systematic reviews have demonstrated that topical estriol at therapeutic concentrations produces minimal to no measurable increase in serum estrogen — making it the preferred choice for topical estrogen therapy in many European and North American clinical protocols.

Active Ingredient

Tretinoin + Estriol
The Night Renewal Protocol

Tretinoin (all-trans retinoic acid) is among the most extensively studied topical actives for skin aging — and its combination with estriol creates a synergistic protocol with clinical support from independent trials.

Tretinoin 0.05%

Retinoid · Cell Renewal

  • Binds retinoic acid receptors (RARα/γ) in keratinocytes
  • Accelerates epidermal turnover (normalization of cell cycling)
  • Inhibits MMP-1 collagenase — reduces collagen breakdown
  • Stimulates new collagen deposition (0.025–0.1% effective range)
  • Proven reduction in fine lines, mottled pigmentation, coarseness

Kligman et al., 1986 · Griffiths et al., 1993 · Varani et al., 2000

Estriol 0.03%

Estrogen · Barrier Support

  • Maintains stratum corneum hydration during retinoid-accelerated turnover
  • Reduces retinoid dermatitis risk via ERβ-mediated keratinocyte modulation
  • Supports lamellar body secretion for barrier lipid maintenance
  • Provides complementary receptor pathway activation overnight
  • Low-dose formulation minimizes any systemic contribution

Verdier-Sévrain, 2007 · Thornton, 2013 (NAMS)

The Combination Advantage

Synergistic Outcomes

  • Tretinoin drives epidermal renewal; estriol prevents barrier disruption
  • Dual stimulation of collagen — via RAR and ER pathways simultaneously
  • Retinoid-induced desquamation supported by estrogen-mediated ceramide production
  • Night-optimized delivery aligns with circadian skin repair biology

Combined Rx protocols — Alloy Women's Health, 2022–2024

Active Ingredients

Non-Hormonal Actives
For every skin, every stage

The RevelleCare Non-Hormonal Repair Cream delivers a high-performance antioxidant and peptide protocol for women seeking proven results without hormonal therapy.

B3

Niacinamide (Vitamin B3)

Barrier · Pigmentation · Anti-inflammatory

Clinically shown to reduce hyperpigmentation, improve barrier function, and decrease inflammatory mediators implicated in skin aging. Stimulates ceramide synthesis and reduces transepidermal water loss by up to 24%.

Bissett et al., 2005 · Levin & Maibach, 2010

C

L-Ascorbic Acid (Vitamin C)

Antioxidant · Collagen · Brightening

Essential cofactor for collagen hydroxylase enzymes. Neutralizes UV-generated reactive oxygen species, reduces melanin synthesis, and stimulates collagen I and III production in fibroblasts independent of hormonal pathways.

Telang, 2013 · Pullar et al., 2017

E

Tocopherol (Vitamin E)

Antioxidant · Barrier · Photoprotection

Lipid-soluble antioxidant that integrates into cell membranes to protect against oxidative stress. Synergizes with Vitamin C (4:1 ratio) for superior free radical neutralization. Supports barrier lipid integrity in post-menopausal skin.

Thiele & Ekanayake-Mudiyanselage, 2007

Pep

Bioactive Peptides

Collagen Signalling · Firming · Renewal

Matrikine peptides (e.g., Palmitoyl Tripeptide-1, Tetrapeptide-7) act as collagen synthesis signals — mimicking the degradation fragments that trigger fibroblast collagen production. In clinical trials, tetrapeptides demonstrate 44% reduction in wrinkle depth and 30% improvement in skin firmness at 12 weeks.

Robinson et al., 2005 · Lintner & Peschard, 2000

Clinical References

  1. Castelo-Branco C, Duran M, González-Merlo J. Skin collagen changes related to age and hormone replacement therapy. Maturitas. 1992;15(2):113-119.
  2. Moraes ABCBM, Haidar MA, Soares JM Jr, Simões MJ, Baracat EC, Patriarca MT. The effects of topical isoflavones on postmenopausal skin: double-blind and randomized clinical trial of efficacy. Eur J Obstet Gynecol Reprod Biol. 2009;146(2):188-192.
  3. Schmidt JB, Binder M, Demschik G, Bieglmayer C, Reiner A. Treatment of skin aging with topical estrogens. Int J Dermatol. 1996;35(9):669-674.
  4. Fuchs KO, Solis O, Tapawan R, Paranjpe J. The effects of an estrogen and glycolic acid cream on the facial skin of postmenopausal women. Cutis. 2003;71(6):481-488.
  5. Thornton MJ. The biological actions of estrogens on skin. Exp Dermatol. 2002;11(6):487-502.
  6. Verdier-Sévrain S. Effect of estrogens on skin aging and the potential role of selective estrogen receptor modulators. Climacteric. 2007;10(4):289-297.
  7. Griffiths CE, Kang S, Ellis CN, et al. Two concentrations of topical tretinoin (retinoic acid) cause similar improvement of photoaging but different degrees of irritation. Arch Dermatol. 1995;131(9):1037-1044.
  8. Varani J, Warner RL, Gharaee-Kermani M, et al. Vitamin A antagonizes decreased cell growth and elevated collagen-degrading matrix metalloproteinases and stimulates collagen accumulation in naturally aged human skin. J Invest Dermatol. 2000;114(3):480-486.
  9. Bissett DL, Oblong JE, Berge CA. Niacinamide: A B vitamin that improves aging facial skin appearance. Dermatol Surg. 2005;31(7 Pt 2):860-865.
  10. Draelos ZD, Alloy Women's Health. Clinical evaluation of topical estriol 0.3% on skin elasticity and moisture. Alloy Internal Clinical Data. 2024.
  11. Brincat M, Moniz CF, Studd JW, et al. Sex hormones and skin collagen content in postmenopausal women. Br Med J. 1983;287(6402):1337-1338.
  12. Kligman AM, Dogadkina D, Lavker RM. Effects of topical tretinoin on non-sun-exposed protected skin of the elderly. J Am Acad Dermatol. 1993;29(1):25-33.

Medical Disclaimer

The clinical evidence presented on this page is for informational purposes only and does not constitute medical advice. RevelleCare products require a valid Canadian prescription issued by a licensed physician. Individual results may vary. Consult your healthcare provider before starting any new treatment.

Ready to Begin

The science is clear.
Your skin deserves it.

Join the RevelleCare waitlist and be the first to know when we launch in Fall 2026 in Ontario & British Columbia.